Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642605 | 0.81 | KMT2A (0.49) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3145134 | 0.79 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL2003409 | 0.79 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27779605 | 0.78 | KMT2A (0.47) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL26808118 | 0.78 | KMT2A (0.54) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL19347554 | 0.76 | POLB (0.56) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL21465398 | 0.76 | CA12 (0.38) | KMT2AMEN1POLBALDH1A1CA12 | |
| SCHEMBL19913410 | 0.76 | KMT2A (0.45) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL23850646 | 0.75 | ADORA2A (0.36) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL21468599 | 0.75 | CA12 (0.37) | KMT2AMEN1POLBALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4565212-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250099425-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119033710-A | Pharmaceutical composition for treating cystic fibrosis | 弗特克斯药品有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-111818918-B | Pharmaceutical composition for treating cystic fibrosis | 弗特克斯药品有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2007046747-A1 | NOVEL BICYCLIC SULFONAMIDES FOR USE AS GLUCOCORTICOID RECEPTOR MODULATORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| EP-0087780-B2 | Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL IND LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| EP-0095925-B2 | Herbicidal imidazole, pyrazole, thiazole and isothiazole derivatives | DU PONT (US) | 1994-12-07 | — | — | EP | disclosed |
| US-4954164-A | Pyrazolesulfonylurea derivatives, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
| US-4946496-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-08-07 | — | — | US | disclosed |
| US-4931081-A | Herbicidal diazoles sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0095925-B1 | HERBICIDAL IMIDAZOLE, PYRAZOLE, THIAZOLE AND ISOTHIAZOLE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-22 | — | — | EP | disclosed |
| EP-0095925-A2 | Herbicidal imidazole, pyrazole, thiazole and isothiazole derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-12-07 | — | — | EP | disclosed |
| EP-0087780-A2 | Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | KMT2A 3014/4885MEN1 1794/4885POLB 2643/4885 |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, TMEM109 | KMT2A 4439/4885MEN1 3338/4885POLB 4282/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | KMT2A 4757/4885MEN1 3673/4885POLB 3928/4885 |
| US-20250099425-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | CFTR, PKD1, ABCB11 | KMT2A 4630/4885MEN1 1520/4885POLB 1800/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | KMT2A 4813/4885MEN1 4316/4885POLB 3212/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | KMT2A 1937/4885MEN1 2277/4885POLB 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.